7 January 2016 - The PBAC decided not to recommend pirfenidone for PBS listing for idiopathic pulmonary fibrosis on the basis of unacceptably high and uncertain cost-effectiveness.

For more details, go to: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2015-11/first-time-decisions-not-to-recommend-2015-11.pdf